MedTrace Logo

Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis

NCT02744755 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 353

Last updated 2018-12-19

Study results available
· View outcomes & findings →

Summary

Clinical trial to compare treatment with GP2017 and Humira® in patients with Rheumatoid Arthritis

Conditions

Interventions

BIOLOGICAL

Adalimumab - GP2017

Adalimumab - GP2017

BIOLOGICAL

Adalimumab - US licensed Humira

Adalimumab - US licensed Humira

Sponsors & Collaborators

  • Hexal AG

    collaborator INDUSTRY

  • Sandoz

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2017-01-31
Completion
2017-09-26

Countries

  • United States
  • Czechia
  • Germany
  • Hungary
  • Italy
  • Malaysia
  • Mexico
  • Poland
  • Romania
  • Russia
  • Serbia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02744755 on ClinicalTrials.gov